What Happened to Corinthian Colleges Inc?

Corinthian Colleges Inc(OTCMKTS:COCOQ) has continued to sink lower in recent months hitting an all-time low of $0.0006; a sad end indeed for a stock that once commanded $35 a share.<br /> This comes after the Company announced the closure of its remaining 28 campus based locations, displacing an estimated 16,000 current students. “We are certainly troubled to see the abrupt closure of so many Everest, WyoTech and Heald Colleges in many cities in California as well in Phoenix, AZ,” said Dr. FardadFateri, president & CEO of International Education Corporation.<br /> <br /> Corinthian Colleges Inc (NASDAQ:COCOQ) used to be a bellwether among for-profit colleges boasting several billion a year in revenues and a student base of several hundred thousand not sore any more.<br /> <br /> Enrollment has declined significant while COCO has been under constant scrutiny from regulators. The for-profit education industry has been criticized for recruiting students most-likely to qualify for government-backed student loans, yet not improving their job prospects after graduation.<br /> <br /> Back in July COCO reached an agreement with the Department of Education to sell most of its campuses or close them down. Some 85 of its 107 campuses are on the block, but the company has yet to find a buyer. Corinthian disclosed late last week that an accreditation agency is examining its placement records:<br /> <br /> Corinthian offers post-secondary career education through its Everest, Heald and WyoTech campuses, as well as online. Program areas include health care, business, criminal justice, transportation technology and maintenance, construction trades and information technology.<br /> <br /> COCO mission is to help students prepare for careers in demand or to advance in their chosen field. With more than 81,300 students as of June 30, 2013, we are one of the largest post-secondary education companies in the U.S. and Canada. We offer short-term diploma programs and associate, bachelor’s, and master’s degrees. Our main program areas include health care, criminal justice, business, information technology, transportation technology and maintenance, and construction trades. In addition, we offer online degree programs that include business, accounting, criminal justice, paralegal and information technology.<br /> <br /> As of June 30, 2013, COCO had approximately 81,300 students and 15,200 employees, including 6,000 faculty. They serve students and operate our schools in keeping with our core values, including integrity, service, excellence and accountability.<br /> <br /> On February 11 COCO said it received a letter on February 5, 2015 from The NASDAQ Stock Market notifying the Company that trading of the Company’s common stock will be suspended from The NASDAQ Capital Market at the opening of business on February 17, 2015 and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission which will remove the Company’s securities from listing and registration on NASDAQ, as a result of its failure to comply with NASDAQ Listing Rule 5250(c)(1). The Rule requires timely filing of periodic reports with the SEC and the Company has not timely filed its Annual Report on Form 10-K for its fiscal year ended June 30, 2014 and its Quarterly Reports on Form 10-Q for its fiscal quarters ended September 30, 2014 and December 31, 2014. The Company was previously granted an exception by NASDAQ until January 30, 2015 to regain compliance with the Rule, however the Company has not been able to file these periodic reports.<br /> <br /> As previously disclosed in a Report on Form 8-K filed with the SEC on July 7, 2014, the Company entered into an Operating Agreement (the “Operating Agreement”) with the U.S. Department of Education which became effective on July 8, 2014, and which, among other things, required the Company to produce certain documents within certain time periods, teach out and close 12 of its schools, and pursue selling the remainder of its Title IV-eligible schools.<br /> <br /> Currently drifting into oblivion on little volume or interest from Investors COCOQ is in dire straits; already bankrupt and under serious investigation, their filings late and the stock delisted to the OTCBB that now bears a ”pink limited information” designation from OTCMarkets it appears the commons will end up worthless; a sad end indeed for a stock that once commanded $35 a share. <br /> <br /> <div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhqoILh3wB5m1-4ljNPefH0TRnvKXFdqzwuM7FAvTODq8PQNkw4Be6dL98HVvp_zmgRyF2_Qrwx64BwYq4yy0D5tLI-h4ZKxsodBTZPzv-8D4pveJ08QaNWJf4DlvFfcDN6EloczhOXzQYJ/s1600/1-1.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhqoILh3wB5m1-4ljNPefH0TRnvKXFdqzwuM7FAvTODq8PQNkw4Be6dL98HVvp_zmgRyF2_Qrwx64BwYq4yy0D5tLI-h4ZKxsodBTZPzv-8D4pveJ08QaNWJf4DlvFfcDN6EloczhOXzQYJ/s400/1-1.jpg" /></a></div>

featured

What Happened to Corinthian Colleges Inc?

Corinthian Colleges Inc(OTCMKTS:COCOQ) has continued to sink lower in recent months hitting an all-time low of $0.0006; a sad end indeed for...

Running With Plandai Biotechnology

Plandai Biotechnology Inc (OTCMKTS:PLPL) has had a year and a half that Investors would love to forget as the stock has continue to lose ground falling from several dollars a share to recent lows near a dime.<br /> <br /> <br /> <br /> PLPL has a long history of big moves making a spectacular run back in early 2015 when pot stocks got hot and ruled the bb’s running from pennies to highs well over $3 a share.<br /> <br /> Plandai Biotechnology Inc (OTCMKTS:PLPL) and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaì Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare(TM) extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.<br /> <br /> The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.<br /> <br /> PLPL products include Phytofare™ Catechin Complex, a water-soluble powder, Ph2™ Topical Catechin Complex, a topical cream that has Phytofare™ nano-entrapped in Pheroid™, Ph2™ Oral Catechin Complex, a gel tab version of Phytofare™ nano-entrapped in Pheroid™, suitable for oral consumption, and Ph2™ Liquid Catechin Complex, an oral version of Phytofare™ nano-entrapped in Pheroid™ in a liquid suspension, suitable for mixing into beverages and liquid medications.<br /> <br /> Last year PLPL started two clinical trials. The first includes 35 participants and focuses on the depth of penetration of the company’s Phytofare™ Pheroid™ Catechin Complex to demonstrate that Plandaí’s product can be effectively used in topical creams to deliver Phytofare™ into target tissues. The second clinical trial includes 35 participants, and focuses on the anti-inflammatory properties of Plandaí’sPhytofare™ Pheroid™ Catechin Complex. The company’s goal is to show reduced redness and irritation in a topical application which will allow Phytofare™ to be used in various skin care products.<br /> <br /> <br /> <br /> <br /> <br /> Plandaì Biotechnology – Uruguay, SA, a wholly owned subsidiary of Plandaì Biotechnology, is currently the only company given authorization to grow cannabis and conduct medical research in Uruguay. Published research indicates that Plandaì’s proprietary extraction process should render the complete cannabinoid complex from the live plant while retaining the acid forms of THC, which are devoid of psychotropic effects. The result should be a highly bioavailable extract that retains all of the potential medical benefits of cannabis without the psychoactive properties. Plandaì intends to establish a pharmaceutical platform in once the initial scientific investigations have been successfully completed.<br /> <br /> On August 26 PLPL announced Ultimate Sports Nutrition (USN) is investigating and developing a new line of products for the Australian and New Zealand markets that incorporates Plandaí’s green tea catechin-based Phytofare® ingredient. Under the terms of a previously announced agreement, USN is committed to using Phytofare® catechin complex exclusively in all products manufactured or sold in Europe and South Africa that incorporate green tea.<br /> <br /> In an effort to further develop and expand on the existing agreement, the Company and USN agreed to allow USN to explore the use of Phytofare® with other USN contract manufacturers, beginning in Australia and New Zealand, in an attempt to determine whether further expansion of the relationship between the Company and USN was desirable.<br /> <br /> Currently trading at a $20 million market valuation PLPL has minimal assets or revenues and a significant debt problem with $15 million in payables (that can lead to massive dilution) PLPL is an exciting Company known as the producer of the highly bioavailable Phytofare® catechin complex. <br /> <div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjzNzMdKNrEleIrQA-70P_RkDGMffNF-uXHOtNOldw2_RPSylP4LDtIwu7o-xPwtp7bJj4MKjIke-xZU1FeTwkPGsEY9inRTousiNpQ2YNzdWAlHybt5Mi83QSMNVwojLuQqHF30PwPpw0n/s1600/2%25281%2529.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjzNzMdKNrEleIrQA-70P_RkDGMffNF-uXHOtNOldw2_RPSylP4LDtIwu7o-xPwtp7bJj4MKjIke-xZU1FeTwkPGsEY9inRTousiNpQ2YNzdWAlHybt5Mi83QSMNVwojLuQqHF30PwPpw0n/s400/2%25281%2529.jpg" /></a></div>

featured

Running With Plandai Biotechnology

Plandai Biotechnology Inc (OTCMKTS:PLPL) has had a year and a half that Investors would love to forget as the stock has continue to lose gro...

Riding The PURE Bioscience Express

Riding The PURE Bioscience Express <br /> PURE Bioscience (OTCMKTS:PURE) has continued to move higher in recent months on accelerating volume since reversing off $0.34 lows back in May.<br /> <br /> <br /> <br /> PURE was delisted from the NASDAQ stock exchange in May of last year for failing to meet the $1 minimum bid requirement. Ironically the stock has been rising since hitting the OTCBB recently surpassing the $1 mark.<br /> <br /> PURE Bioscience (OTCMKTS:PURE) is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena — providing solutions to the health and environmental challenges of pathogen and hygienic control.<br /> <br /> PURE technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.<br /> <br /> PURE Hard Surface disinfectant, which is powered by the patented, non-toxic, environmentally friendly SDC antimicrobial molecule, fits perfectly into SUBWAY(R)’s commitment to greener living and its food safety protocol. A leader in the quick service restaurant industry, all SUBWAY(R) restaurants are required to follow policies in support of SUBWAY(R)’s overall commitment to make its restaurants and operations as environmentally and socially responsible as possible. The availability of the powerful PURE Hard Surface disinfectant will strengthen the quick service restaurant chain’s sanitization program.<br /> <br /> Earlier this year PURE announced the resignation of Peter C. Wulff as its Chief Financial Officer and Chief Operating Officer. Wulff informed the Company that he has accepted a new assignment as CFO for a venture-backed medical device company.<br /> <br /> With Wulff’s departure, Mark Elliott, PURE’s Controller, has been promoted and will play a new leadership role in PURE’s Finance department as the Company’s Vice President, Finance and will serve as the Company’s principal financial and accounting officer. Elliott joined PURE in 2004 and has been responsible for managing all accounting and regulatory reporting activities since May 2006. He has also been responsible for establishing all current financial and reporting systems. Prior to joining PURE, Elliott worked in government accounting. He earned a Bachelor of Science, Business Administration-Accountancy at California State University-San Marcos.<br /> <br /> On September 17 PURE it has received an Acknowledgement Letter from the US Food and Drug Administration (FDA) stating that its Food Contact Notification (FCN) for Silver Dihydrogen Citrate (SDC) as a raw poultry processing aid is complete and setting an effective date of December 2015.<br /> <br /> The next step in the regulatory approval process is to obtain USDA approval. With its receipt of the FDA’s Acknowledgement Letter, PURE is now eligible to initiate this next step. Accordingly, after its receipt of the Acknowledgement Letter from the FDA, PURE immediately submitted its FCN to the Food Safety and Inspection Service of the USDA to commence the USDA review and approval process.<br /> <br /> As part of the USDA process, PURE is preparing to conduct in-plant process validation and optimization trials with the authorization of the USDA. At the completion of the trials, PURE expects the USDA to issue a “Letter of No Objection” and list SDC as an approved on line reprocessing poultry processing aid in Attachment 1, table 1 of the FSIS Directive 7120.1, Safe and Suitable Ingredients Used in the Production of Meat, Poultry and Egg Products.<br /> <br /> Currently trading at a $30 million market valuation PURE does have $3.9 million in the treasury as well as some small revenues. PURE is an exciting story developing in small caps; the Company is the creator of the patented silver dihydrogen citrate (SDC) antimicrobial and an ex NASDAQ stock with several irons in the oven.<br /> <div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgjf2AwMqImXGfU5lXb5O7sL2UxypmEurqXq5204cVTN9wAiTKqkYEgblTudHswsCgCn44DwS_Dxjn6M_U9ftOgN1TH2joA8aOPSLYIcYlHOsiQFeZBaR9x9aFoHHNYlly-1vds3DqfZ3ZZ/s1600/3-1.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgjf2AwMqImXGfU5lXb5O7sL2UxypmEurqXq5204cVTN9wAiTKqkYEgblTudHswsCgCn44DwS_Dxjn6M_U9ftOgN1TH2joA8aOPSLYIcYlHOsiQFeZBaR9x9aFoHHNYlly-1vds3DqfZ3ZZ/s400/3-1.jpg" /></a></div>

featured

Riding The PURE Bioscience Express

Riding The PURE Bioscience Express PURE Bioscience (OTCMKTS:PURE) has continued to move higher in recent months on accelerating volume sinc...